Efficacy and Safety of IV Levetiracetam in Children With Acute Repetitive Seizures

İşgüder, Rana; Güzel, Orkide; Ağın, Hasan; Yılmaz, Ünsal; Akarcan, Sanem Eren; Çelik, Tanju; Ünalp, Aycan

doi:10.1016/j.pediatrneurol.2014.07.021

Cited by 14 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…described side effects such as agitation and aggression in 3/133 patients. [ 16 ] We found agitation and aggression in two patients, and mild erythematous rash and urticaria in one patient. LEV was discontinued in those three patients, and their symptoms were resolved.…”

Section: Discussionmentioning

confidence: 92%

“…In a study by İşgüder et al ., it is found in 78.2% of the whole study population (133 patients). [ 16 ] In other studies, such as McTague et al . and Reiter et al ., IV LEV treatment was reported to have totally controlled seizures in 62% and 67% of children, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…described that there was no significant difference of the response rate between the different etiologies of seizures (symptomatic, cryptogenic, and idiopathic). [ 16 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 26 ] Recently, there are reports that LEV may be safe and effective for treating SE and ARS in children. [ 6 15 16 17 ] Nau et al . reported no adverse hemodynamic events or cardiac arrhythmias in their study.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Intravenous levetiracetam in critically ill children

İncecik

Horoz

Hergüner

et al. 2016

Ann Indian Acad Neurol

View full text Add to dashboard Cite

Background:To report the effectiveness and safety of intravenous (IV) levetiracetam (LEV) in the treatment of critically ill children with acute repetitive seizures and status epilepticus (SE) in a children's hospital.Materials and Methods:We retrospectively analyzed data from children treated with IV LEV.Results:The mean age of the 108 children was 69.39 ± 46.14 months (1-192 months). There were 58 (53.1%) males and 50 (46.8%) females. LEV load dose was 28.33 ± 4.60 mg/kg/dose (10-40 mg/kg). Out of these 108 patients, LEV terminated seizures in 79 (73.1%). No serious adverse effects were observed but agitation and aggression were developed in two patients, and mild erythematous rash and urticaria developed in one patient.Conclusion:Antiepileptic treatment of critically ill children with IV LEV seems to be effective and safe. Further study is needed to elucidate the role of IV LEV in critically ill children.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

“…described that there was no significant difference of the response rate between the different etiologies of seizures (symptomatic, cryptogenic, and idiopathic). [ 16 ]…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Intravenous levetiracetam in critically ill children

İncecik

Horoz

Hergüner

et al. 2016

Ann Indian Acad Neurol

View full text Add to dashboard Cite

show abstract

“…However, there are limited data on the efficacy of i.v. LEV for SE and ARS in children 12 14 15 16 17 18 19) . McTague et al 12) reported that i.v.…”

Section: Discussionmentioning

confidence: 99%

Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures

et al. 2016

View full text Add to dashboard Cite

PurposeThis study compared the efficacy and tolerability of intravenous (i.v.) phenobarbital (PHB) and i.v. levetiracetam (LEV) in children with status epilepticus (SE) or acute repetitive seizure (ARS).MethodsThe medical records of children (age range, 1 month to 15 years) treated with i.v. PHB or LEV for SE or ARS at our single tertiary center were retrospectively reviewed. Seizure termination was defined as seizure cessation within 30 minutes of infusion completion and no recurrence within 24 hours. Information on the demographic variables, electroencephalography and magnetic resonance imaging findings, previous antiepileptic medications, and adverse events after drug infusion was obtained.ResultsThe records of 88 patients with SE or ARS (median age, 18 months; 50 treated with PHB and 38 with LEV) were reviewed. The median initial dose of i.v. PHB was 20 mg/kg (range, 10–20 mg/kg) and that of i.v. LEV was 30 mg/kg (range, 20–30 mg/kg). Seizure termination occurred in 57.9% of patients treated with i.v. LEV (22 of 38) and 74.0% treated with i.v. PHB (37 of 50) (P=0.111). The factor associated with seizure termination was the type of event (SE vs. ARS) in each group. Adverse effects were reported in 13.2% of patients treated with i.v. LEV (5 of 38; n=4, aggressive behavior and n=1, vomiting), and 28.0% of patients treated with i.v. PHB (14 of 50).ConclusionIntravenous LEV was efficacious and safe in children with ARS or SE. Further evaluation is needed to determine the most effective and best-tolerated loading dose of i.v. LEV.

show abstract

Antikonvulsive Behandlung bei Kindern mit therapieschwierigen Epilepsien

Vieker

Schmitt

2016

Z. Epileptol.

View full text Add to dashboard Cite

Efficacy and Safety of IV Levetiracetam in Children With Acute Repetitive Seizures

Cited by 14 publications

References 42 publications

Intravenous levetiracetam in critically ill children

Intravenous levetiracetam in critically ill children

Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures

Antikonvulsive Behandlung bei Kindern mit therapieschwierigen Epilepsien

Contact Info

Product

Resources

About